The two companies want to drive forward a BioVersys program for the treatment of non-tuberculous mycobacteria.
Keystone / Gaetan Bally
Swiss biotech firm BioVersys has signed a research and licensing agreement with the Japanese pharmaceutical company Shionogi.
+Get the most important news from Switzerland in your inbox
Under the terms of the collaboration, BioVersys is entitled to upfront and short-term research payments of CHF5 million, as the Basel-based company announced on Wednesday.
Should Shionogi exercise a license option, approval and sales-based payments of up to CHF479 million ($604 million) tiered royalties on future sales would be added.
+ BioVersys is first Swiss IPO of 2025
The two companies want to drive forward a BioVersys program for the treatment of non-tuberculous mycobacteria. These pathogens can cause lung and skin infections and pathological swelling of the lymph nodes, particularly in people with weakened immune systems.
Translated from German by DeepL/jdp
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch
